葡萄糖大脑化酶活动的缺陷超出了戈舍病:PSAP和LIMP-2功能障碍
Eleonora Pavan1, Paolo Peruzzo1, Silvia Cattarossi1
1Regional Coordinator Centre for Rare Diseases, University Hospital of Udine, 33100 Udine, Italy.
International journal of molecular sciences
|June 27, 2024
概括
氏病 (GD) 可能源于GBA1,PSAP或SCARB2基因的突变. 我们为GCase缺乏症确定了不同的生物标志物概况,揭示了酶降解途径的差异.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 溶酶体储存疾病 溶酶体储存疾病
背景情况:
- 葡萄糖脑化酶 (GCase) 缺乏导致高氏病 (GD),主要是由于GBA1基因的突变.
- GCase的活性依赖于其激活因子 Saposin C (SapC) 和 lysosomal 向因子 LIMP-2,分别由 PSAP 和 SCARB2 基因编码.
- 在SapC或LIMP-2中罕见的缺陷也会损害GCase功能,导致类似GD的表型.
研究的目的:
- 报告LIMP-2和SapC缺陷的新病例.
- 分析和比较由PSAP,SCARB2和GBA1基因突变引起的GCase缺陷的生物化学特征.
- 研究LIMP-2和PSAP缺乏细胞中的GCase降解途径.
主要方法:
- 关于LIMP-2和SapC缺陷的案例报告.
- 在血中测量高氏病生物标志物 (例如,葡萄糖,基托酶活性).
- 在患者衍生的纤维细胞和白细胞中评估GCase活性.
- 使用蛋白质酶和 lysosomal 抑制剂对 GCase 降解途径的分析.
主要成果:
- 在所有GCase缺乏症中,血葡萄糖氨酸的含量都升高,而在PSAP和GBA1缺乏症中,基托里奥酶的含量只增加.
- 纤维细胞和白细胞中的GCase活性减少,GBA1和SCARB2缺陷的减少更为明显.
- 在LIMP-2缺乏症中,GCase经历了蛋白质体降解,在PSAP缺乏症中经历了溶解体降解.
结论:
- 独特的生物化学特征区分了由PSAP和SCARB2突变引起的GCase缺陷与由GBA1突变引起的缺陷.
- 这些发现强调了在GCase缺乏症的差异诊断中考虑PSAP和SCARB2的重要性.
- 了解GCase降解途径为不同形式的GCase缺乏症提供了潜在治疗策略的见解.
相关概念视频
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:20Inborn Errors of Metabolism
153
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
153
01:27Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
01:05Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
01:21Overview of Protein Metabolism
991
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
991
01:15Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523